Advocacy intelligence hub — real-time data for patient organizations
Mayo Clinic — PHASE1, PHASE2
Centre Hospitalier Universitaire, Amiens — NA
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
French Innovative Leukemia Organisation — PHASE2
Shayna Sarosiek, MD — PHASE2
BeiGene — PHASE4
Institute of Hematology & Blood Diseases Hospital, China — PHASE1
BeOne Medicines — PHASE2
AbbVie — PHASE1
Dana-Farber Cancer Institute — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Travel grants
Travel Grants1
PAN Foundation Waldenström Macroglobulinemia Disease Fund
PAN Foundation
BRUKINSA
(zanubrutinib)Orphan drugstandardBeOne Medicines USA, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cyste...
IMBRUVICA
(ibrutinib)Orphan drugstandardPharmacyclics, LLC
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine re...
Jorge J Castillo, MD
Dana-Farber Cancer Institute
Shaji Kumar
Mayo Clinic
📍 Anchorage, Alaska
Oliver W. Press, MD, PhD, M.D
Fred Hutchinson Cancer Center
📍 SAN LUIS OBISPO, CA
Thomas Witzig, M.D
Mayo Clinic
📍 ROCHESTER, MN
Rainer Brachmann
BeiGene
Heather Allewelt, MD
BeiGene USA
📍 ORLANDO, FL